title: Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
abstract: We have designed a cyclic regimen for the treatment of osteoporosis based on the activate, depress, free, and repeat (ADFR) concept. Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight). Patients next take calcium supplements for 48 days before resuming phosphate to enter the next cycle. Osteoporotic women increased the bone mineral density of the lumbar spine at 6 months by 7.2 +/- 5.2% (mean +/- SD, N = 14) and at 12 months by 8.2 +/- 4.0% (N = 8). Control observations in regularly exercising postmenopausal women (N = 30) showed no significant change in spine mineral density after 20 months (0.5 +/- 3.2%), confirming the stability of the measurement technique. The two patients who responded poorly to the cyclic regimen each showed a blunted rise in serum PTH during oral phosphate administration, suggesting that the rise in PTH induced by oral phosphate may be an important component of this cyclic regimen. This preliminary study does not identify which component or components of the regimen are responsible for the increase in bone mass but provides positive encouragement for randomized studies designed to determine the optimum dosage, duration, and timing of each component of the regimen.
authors.affiliation: Medicine Service, Veterans Administration Medical Center, Houston, TX 77030.
authors.forename: L E
authors.initials: LE
authors.lastname: Mallette
authors.forename: A D
authors.initials: AD
authors.lastname: LeBlanc
authors.forename: J L
authors.initials: JL
authors.lastname: Pool
authors.forename: J I
authors.initials: JI
authors.lastname: Mechanick
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001862:Bone Resorption / Q000187:drug effects; D002118:Calcium / Q000097:blood; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D013131:Spine / Q000187:drug effects / Q000378:metabolism
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D012968:Etidronic Acid; D002118:Calcium